The global transcatheter mitral valve market is poised for remarkable growth, with projections indicating an increase from USD 1.6 billion in 2024 to USD 3.0 billion by 2034, reflecting a compound annual growth rate (CAGR) of 10.8%. This rapid expansion highlights the increasing demand for advanced cardiac interventions and transformative solutions for patients with mitral valve regurgitation.
The surge in market demand is attributed to several key factors, including the aging global population and the rising incidence of mitral valve regurgitation—a common heart valve condition requiring advanced medical intervention. As healthcare systems around the world face the growing burden of these cardiac diseases, transcatheter mitral valve replacement (TMVR) has emerged as a breakthrough treatment, revolutionizing the approach to mitral valve repair.
Market Trends and Growth Drivers
Transcatheter mitral valve replacement (TMVR) is positioned to play a central role in addressing the challenges of mitral valve disease. However, despite the promising outlook, there remain challenges such as precise valve positioning, anchoring techniques, and the risk of left ventricular outflow tract obstruction. Nonetheless, innovation in the field has led to remarkable improvements, particularly in transapical and transseptal devices, which are showing positive clinical outcomes through ongoing feasibility trials worldwide.
Additionally, several regions are contributing significantly to market growth. The United States is expected to lead the market with a projected CAGR of 12.8%, driven by expanded coverage for transcatheter edge-to-edge treatments under CMS (Centers for Medicare & Medicaid Services). Meanwhile, Germany is also expected to experience strong growth at a CAGR of 10%, supported by favorable reimbursement policies and a booming medical tourism sector. In Asia, China is set to grow at a CAGR of 11.7%, fueled by a high prevalence of rheumatic fever and an increasing emphasis on cardiac health.
Key Market Insights
- The transcatheter mitral valve repair segment dominated the market in 2023, holding an 82.4% share due to its benefits, including improved left ventricular function and reduced complications.
- Hospitals continue to be the largest end user, holding a 36.7% market share in 2023, driven by increased cardiac procedures and ongoing investments in healthcare infrastructure across regions.
- Key factors propelling growth include expanded CMS coverage, rising medical tourism, technological advancements, and a higher prevalence of rheumatic diseases.
The Future of Transcatheter Mitral Valve Therapy
The global transcatheter mitral valve market is not only expanding but also transforming the landscape of mitral regurgitation treatment. As clinical adoption of TMVR continues to rise, combined with ongoing advancements in device technology, the treatment offers renewed hope for patients. With the global medical community committed to improving patient outcomes, the next decade will likely see transcatheter mitral valve replacement redefine the standards of care for cardiovascular diseases.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!
Competitive Landscape:
The global transcatheter mitral valve market is primarily dominated by two industry giants: Abbott and Edwards. Both companies are at the forefront of developing groundbreaking technologies aimed at supporting patients suffering from mitral and tricuspid regurgitation.
These companies have secured licenses and patents for their technologies within this domain. However, the expiration of these licenses and patents could impact the future revenues and operating income of these key players.
Recent Developments:
- April 2024: Medtronic plc announced that the one-year results from the SMART study indicate that the Medtronic Evolut™ TAVR platform is the optimal therapy for severe aortic stenosis in patients with a small annulus, particularly women.
- May 2024: The one-year outcomes from the Bionetic-i study demonstrate the safety and effectiveness of iliac artery treatment using BIOTRONIK’s Dynetic-35 cobalt chromium balloon-expandable stent system.Top of Form
Bottom of Form
Key Players of Transcatheter Mitral Valve Market:
- HLT Inc
- Coramaze Technologies
- Medtronic
- Biotronik
- NeoChord, Inc.
- Colibri Heart Valve LLC
- Neovasc
- Edwards Lifesciences Corporation
- Abbott Laboratories
- LIVANOVA PLC
Key Segments of Transcatheter Mitral Valve Market:
By Product:
In terms of product, the industry is divided into transcatheter mitral valve replacement and transcatheter mitral valve repair.
By Indication:
In terms of indication, the industry is segregated into mitral stenosis and mitral regurgitation.
By End user:
The industry is classified by end user as hospitals, ambulatory surgical centers and cardiac catheterization laboratories
By Region:
Key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa have been covered in the report.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube